Arrowstreet Capital
KROS icon

Arrowstreet Capital’s Keros Therapeutics KROS Stock Holding History

Arrowstreet Capital’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.49M Sell
233,175
-357,074
-60% -$3.98M ﹤0.01% 1478
2026
Q1 		$6.52M Sell
590,249
-744,267
-56% -$11.5M ﹤0.01% 1077
2025
Q4 		$27.2M Buy
1,334,516
+1,075,762
+416% +$18.9M 0.02% 650
2025
Q3 		$4.09M Buy
258,754
+194,173
+301% +$2.87M ﹤0.01% 1233
2025
Q2 		$862K Buy
+64,581
New +$872K ﹤0.01% 1648

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Arrowstreet Capital's KROS Position: Q2 2026 in Review

Arrowstreet Capital reduced its Keros Therapeutics (KROS) stake by 60% in Q2 2026, selling an estimated $3.98M and leaving 233,175 shares worth $2.49M. The position accounts for ﹤0.01% of the portfolio, ranked #1478.

Arrowstreet Capital first reported a position in KROS in Q2 2025 and has held it in 5 quarters since. The position peaked at $27.2M in Q4 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Arrowstreet Capital held 233,175 shares of Keros Therapeutics worth $2.49M as of Q2 2026.
  • Arrowstreet Capital sold 357,074 Keros Therapeutics shares in Q2 2026, an estimated $3.98M.
  • Keros Therapeutics made up ﹤0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #1478 holding.
  • Arrowstreet Capital first reported a position in Keros Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Arrowstreet Capital's Keros Therapeutics position peaked at $27.2M in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.